

# LANXESS – FY/Q4 2022 results

Successfully managing a challenging year

Matthias Zachert, CEO

Michael Pontzen, CFO

# Safe harbor statement

The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.

This presentation contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

# Agenda

**1 Review FY/Q4 2022 and outlook**


**2 Financial and business details FY/Q4 2022**

**3 Appendix**

# FY 2022 earnings increase in difficult environment; progress on strategic agenda


## 2022 strategic and financial highlights

- Portfolio transformation continued in difficult environment
- FY EBITDA pre of €930 m due to successful pricing and acquired businesses contributing
- Raw material, energy and freight costs fully passed on, however weighing on margins
- Working capital burdens FY cash flow with €471 m; inflow from working capital reduction of €126 m in Q4
- Dividend proposal of €1.05 – following our dividend policy
- Climate strategy enhanced with Scope 3 reduction target and overall climate path approval by SBTi




# Successfully managed a challenging year – weak spots are being addressed

**In FY 2022 LANXESS achieved a lot...**



**...and weak spots have priority!**



# Engineering Materials Joint Venture: LANXESS to receive ~€1.1 bn - closing expected early April

## Closing conditions fulfilled

- HPM carve-out completed end of 2022
- Antitrust approvals obtained
- Closing: expected early April 2023
- LXS to receive ~€1.1bn
- JV share will be reflected with a value of ~€1.4 bn in LXS balance sheet

## Capital allocation

- Repayment of hybrid bond at first call date in June 2023 is intended, refinancing to be decided
- Focus is on debt reduction
- Considering investors' feedback, share buy back will not be pursued



Deleveraging




Improving LANXESS portfolio



Creating additional value

# LANXESS remains committed to its dividend policy

## Dividend per share [€]



**2022 dividend – a balanced decision**

## Dividend policy

LANXESS aims for an increasing or at least stable dividend



<sup>1</sup> To be proposed to the Annual General Meeting on May 24, 2023

<sup>2</sup> Based on stock price of €37.70 at year end

# Our road to net zero is on track and externally recognized

## Recent new steps on our road to net zero

### Reduction of Scope 2 emissions: Transition to green electricity supply

- ✓ LANXESS sources green electricity from ENGIE


### Reduction of Scope 3 emissions: Make use of sustainable raw materials

- ✓ LANXESS and TotalEnergies cooperate on sustainable styrene
- ✓ LANXESS and Covestro cooperate to produce more sustainable raw materials with reduced CO<sub>2</sub> footprint

## Our ESG performance is recognized externally



### Dow Jones Sustainability Indices Powered by the S&P Global CSA



**We are one of few chemical companies following an overall 1.5°C pathway, validated by SBTi!**



# LXS Group: Q4 EBITDA stable as Specialty Additives & Consumer Protection offset weaker Adv. Intermediates



**Stable EBITDA pre despite record low utilization**

| [€ m]      | Q4/2021 | Q4/2022 | Δ    | FY 2021 | FY 2022 | Δ   |
|------------|---------|---------|------|---------|---------|-----|
| Sales      | 1,679   | 1,973   | 18%  | 6,101   | 8,088   | 33% |
| EBITDA pre | 172     | 175     | 2%   | 815     | 930     | 14% |
| Margin     | 10.2%   | 8.9%    |      | 13.4%   | 11.5%   |     |
| CAPEX      | 183     | 158     | -14% | 424     | 407     | -4% |


Price **+19%**   Volume **-13%**   FX **+5%**   Portfolio **+7%**

Total **+18%**

Q4 Sales vs. PY

- Significant sales increase in all segments mainly driven by pricing
- Strong volume decline mainly due to customer-destocking
- EBITDA pre reflects strong pricing offset by weak utilization due to customer destocking and own inventory management
- Full pass-through of inflated raw material and energy costs weigh on margin

# FY 2023 guidance: EBITDA pre expected around 2022 level




## Our view on economic environment

- Recessionary environment expected for H1 2023
- Positive effect of passthrough of still high selling prices expected to be offset by customer destocking in Q1 2023 and respective low utilization
- Force Majeure on supply of Chlorine and US winter storms will burden Q1 results (Consumer Protection & Specialty Additives)
- Potential positive impetus from China earliest with Q2

## LANXESS outlook

- **FY guidance:** EBITDA pre expected around 2022 level
- **Focus on cash management:**
  - 2023 target: W/C to sales ratio in low twenties percentage range
  - Capex ~€400 m
- **EBITDA pre Q1 2023 expected: ~€180 – 220 m**



# Agenda

**1 Review FY/Q4 2022 and outlook**

**2 Financial and business details FY/Q4 2022**

**3 Appendix**



# Consumer Protection: IFF MC contribution and pricing drive earnings

**Volumes slightly lower due to high comparable base**


| [€ m]      | Q4/2021 | Q4/2022 | Δ   | FY 2021 | FY 2022 | Δ   |
|------------|---------|---------|-----|---------|---------|-----|
| Sales      | 460     | 640     | 39% | 1,579   | 2,366   | 50% |
| EBITDA pre | 66      | 77      | 17% | 279     | 363     | 30% |
| Margin     | 14.3%   | 12.0%   |     | 17.7%   | 15.3%   |     |
| CAPEX      | 47      | 43      | -9% | 100     | 129     | 29% |

Price **+15%**   Volume **-3%**   FX **+3%**   Portfolio **+24%**

Total **+39%**

Q4 Sales vs. PY

- Sales increase significantly driven by portfolio and successful pricing in all BUs
- Volumes held back by customer-destocking as expected
- Increase in EBITDA pre on basis of IFF MC; margin decline mainly due to idle costs resulting from inventory management and price pass-through
- Force Majeure for Chlorine supply will burden Q1 2023



# Specialty Additives: Margins improving

**FX supports due to strong US footprint**


Price **+18%** Volume **-12%** FX **+7%** Portfolio **+0%**

Total **+13%**

Q4 Sales vs. PY

| [€ m]      | Q4/2021 | Q4/2022 | Δ    | FY 2021 | FY 2022 | Δ    |
|------------|---------|---------|------|---------|---------|------|
| Sales      | 605     | 684     | 13%  | 2,295   | 2,970   | 29%  |
| EBITDA pre | 58      | 88      | 52%  | 323     | 479     | 48%  |
| Margin     | 9.6%    | 12.9%   |      | 14.1%   | 16.1%   |      |
| CAPEX      | 69      | 54      | -22% | 139     | 125     | -10% |

- Increase in sales in all BUs, driven by strong pricing and FX
- Volume softer due to customer-destocking and weaker demand in construction affecting BU PLA and auto impacting BU RCH
- EBITDA pre and margin increased compared to weak previous year thanks to positive pricing
- Impact from US winter storms will burden Q1 2023



# Advanced Intermediates: Hit by low utilization

**Volumes affected  
by lower demand  
and destocking**

| [€ m]      | Q4/2021 | Q4/2022 | Δ    | FY 2021 | FY 2022 | Δ    |
|------------|---------|---------|------|---------|---------|------|
| Sales      | 539     | 571     | 6%   | 1,949   | 2,413   | 24%  |
| EBITDA pre | 92      | 65      | -29% | 333     | 291     | -13% |
| Margin     | 17.1%   | 11.4%   |      | 17.1%   | 12.1%   |      |
| CAPEX      | 41      | 35      | -15% | 119     | 95      | -20% |

Price **+25%** Volume **-22%** FX **+3%** Portfolio **0%**

Total **+6%**



Q4 Sales vs. PY

- Slight sales increase due to price pass-through and IFRS15 effect
- Volumes dropped massively in both BUs caused by low demand (mainly construction) and customer-destocking
- Against strong prior year EBITDA pre and margin impacted by lower utilization partly driven by own inventory control measures

# Improvement in Working Capital in Q4 2022 mainly driven by inventory and receivables reduction

Focus across all BUs is on improving W/C

W/C in €m




2023 target: W/C to sales ratio in low twenties percentage range

# Successful price pass through in 2022

2022 price increases reflect full pass on of raw material, energy & freight costs

Change in prices of cost lines YoY\* in €m



- In 2021 raw material prices fully passed on and started to pass on energy costs
- FY 2022 full pass through of raw material, energy and freight cost inflation; catch up of lag of price pass on in 2021
- Uncertainty regarding price developments in 2023 and overall impact of demand situation

**Pricing power proven in a challenging environment**



# P&L Q4: Earnings stable despite volume decline

| [€ m]*                    | Q4/2021            |        | Q4/2022           |        | yoy in %    |
|---------------------------|--------------------|--------|-------------------|--------|-------------|
| Sales                     | 1,679              | (100%) | 1,973             | (100%) | 18%         |
| Cost of sales             | -1,294             | (-77%) | -1,519            | (-77%) | 17%         |
| Selling                   | -240               | (-14%) | -291              | (-15%) | 21%         |
| G&A                       | -83                | (-5%)  | -100              | (-5%)  | 20%         |
| R&D                       | -24                | (-1%)  | -26               | (-1%)  | 8%          |
| Financial result          | -8                 |        | -25               |        | >100%       |
| <b>Net Income (cont.)</b> | <b>-8</b>          |        | <b>-14</b>        |        | <b>75%</b>  |
| <b>EPS pre (cont.)</b>    | <b>0.64</b>        |        | <b>0.47</b>       |        | <b>-27%</b> |
| EBITDA                    | 123                | (7%)   | 153               | (8%)   | 24%         |
| thereof except.           | -49                | (-3%)  | -22               | (-1%)  | -55%        |
| <b>EBITDA pre except.</b> | <b>172 (10.2%)</b> |        | <b>175 (8.9%)</b> |        | <b>2%</b>   |

- Successful pass-through of inflated input costs. However, margin impacted by arithmetic effect and volume decline
- Higher selling expenses result from ongoing higher freight costs and portfolio effect
- Increased G&A due to portfolio and FX effect
- Financial result mainly impacted by valuation of financial instruments (Standard Lithium)

# Cash flow: Successfully managing working capital in Q4

| [€ m]                           | Q4/2021     | Q4/2022    | Δ           |
|---------------------------------|-------------|------------|-------------|
| <b>Profit before tax</b>        | <b>-12</b>  | <b>-21</b> | <b>-9</b>   |
| Income taxes                    | 19          | -33        | -52         |
| Changes in other assets & liab. | 8           | -154       | -162        |
| Changes in working capital      | 76          | 126        | 50          |
| <b>Operating cash flow</b>      | <b>223</b>  | <b>92</b>  | <b>-131</b> |
| <b>Investing cash flow</b>      | <b>-462</b> | <b>14</b>  | <b>476</b>  |
| thereof capex                   | -183        | -158       | 25          |

- Income tax 2021 includes reimbursements
- Changes in other assets and liabilities reflect among others:
  - Exceptional cash out due to German EEG (renewable energy law) payments
  - Variable compensation
  - Non-cash effect of IFRS15 and FX hedging with positive effects in 2021
- Measures to improve working capital show first effect
- Capex reduced below previous year level

# Portfolio and FX with biggest impact on balance sheet

| [€ m]                                 | 31.12.2021    | 31.12.2022 <sup>1</sup> |
|---------------------------------------|---------------|-------------------------|
| <b>Total assets</b>                   | <b>10,528</b> | <b>11,281</b>           |
| Equity                                | 3,762         | 4,427                   |
| <b>Equity ratio</b>                   | <b>36%</b>    | <b>39%</b>              |
| <b>Net financial debt<sup>2</sup></b> | <b>2,245</b>  | <b>3,814</b>            |
| <b>Pension provisions</b>             | <b>877</b>    | <b>367</b>              |
| <b>Net working capital</b>            | <b>1,675</b>  | <b>2,009</b>            |
| DSI (in days) <sup>3</sup>            | 71            | 85                      |
| DSO (in days) <sup>3</sup>            | 45            | 39                      |


- Higher total assets mainly driven by portfolio effect (IFF MC) and FX
- Higher equity due to positive net income and OCI effects (especially pensions and FX)
- Financial debt increased by payment of purchase price of IFF MC and working capital inflation
- Reduced pension provisions due to strong asset performance and increased interest rates
- Working capital increase based on portfolio effect, inflated input costs and FX

<sup>1</sup> BU HPM accounted as “discontinued operations”: Assets & related liabilities of BU HPM summarized in one line item only and no longer included in presented line items (except total assets, equity)

<sup>2</sup> Including cash, cash equivalents, near cash assets, short-term money market investments

<sup>3</sup> Days sales of inventory / sales outstanding calculated from quarterly sales

# Q4 2022: Strong earnings increase in Consumer Protection and Specialty Additives




<sup>1</sup> Total group sales including all other segments


<sup>2</sup> Lower result due to FX hedges, inflated costs due to stronger USD and remnant costs

# Q4 2022: Growth in all regions except Asia

Q4 2022 sales by region [%]



Regional development of sales [€ m]



# Agenda

**1 Review FY/Q4 2022 and outlook**

**2 Financial and business details FY/Q4 2022**

**3 Appendix**

# Housekeeping items 2023


|                                |   |
|--------------------------------|---|
| <b>Capex 2023</b>              | <b>~€400 m</b>  |
| <b>Operational D&amp;A</b>     | <b>~€550 m</b> (thereof <b>~€150 m</b> of intangible amortization effects)            |
| <b>All other segments 2023</b> | <b>~€170 m</b>  |
| <b>Underlying tax rate</b>     | <b>~27%</b>   |
| <b>Exceptionals 2023</b>       | <b>~€80 m</b> based on current initiatives  |
| <b>FX sensitivity</b>          | One cent change of USD/EUR resulting in <b>~€7 m</b> EBITDA pre impact before hedging |

# Synergies from EKC and IFF MC transactions to deliver incremental €15 m in 2023

## Combined synergies of EKC & IFF-MC

Illustrative

Top line synergies



Cost synergies

|           | 2021     | 2022     | 2023   | 2024   | 2025  | Total  |
|-----------|----------|----------|--------|--------|-------|--------|
| Synergies | <€5m ✓   | ~ €15m ✓ | ~ €15m | ~ €15m | ~ €5m | ~ €55m |
| OTCs      | ~ €15m ✓ | ~ €25m ✓ | ~ €15m | ~ €10m | -     | ~ €65m |
| Capex*    | ~ €15m ✓ | ~ €25m ✓ | ~ €20m | ~ €15m | -     | ~ €75m |

## Synergies on track



- Recurring synergies of ~€20m already generated in 2022
- Additional synergies of ~€15m to be realized in 2023
- Cash outs for OTCs and Capex will ease in 2023/24, supporting improved cash flow



# FY 2022: Earnings improved; lower volumes, inflated input costs and arithmetic effect weigh on margins

| [€ m]*                    | FY 2021     |                | FY 2022     |                | yoy in %   |
|---------------------------|-------------|----------------|-------------|----------------|------------|
| Sales                     | 6,101       | (100%)         | 8,088       | (100%)         | 33%        |
| Cost of sales             | -4,576      | (-75%)         | -6,151      | (-76%)         | 34%        |
| Selling                   | -816        | (-13%)         | -1,064      | (-13%)         | 30%        |
| G&A                       | -276        | (-5%)          | -319        | (-4%)          | 16%        |
| R&D                       | -95         | (-2%)          | -102        | (-1%)          | 7%         |
| Financial result          | -48         | (-1%)          | -23         | (0%)           | -52%       |
| <b>Net income (cont.)</b> | <b>115</b>  | <b>(2%)</b>    | <b>184</b>  | <b>(2%)</b>    | <b>60%</b> |
| <b>EPS pre (cont.)</b>    | <b>3.60</b> |                | <b>3.75</b> |                | <b>4%</b>  |
| EBITDA                    | 668         | (11%)          | 826         | (10%)          | 24%        |
| thereof except.           | -147        | (-2%)          | -104        | (-1%)          | -29%       |
| <b>EBITDA pre</b>         | <b>815</b>  | <b>(13.4%)</b> | <b>930</b>  | <b>(11.5%)</b> | <b>14%</b> |


- Increased input costs fully passed on
- Higher selling expenses due to increased freight costs and portfolio effect
- G&A increased due to portfolio and FX effect
- Earnings rose thanks to strong contribution of Specialty Additives and Consumer Protection
- Inflated input and idle costs impact margins

# FY 2022: Operating cash flow burdened by increase in working capital

| [€ m]*                          | FY 2021     | FY 2022     | Δ           |
|---------------------------------|-------------|-------------|-------------|
| <b>Profit before tax</b>        | <b>163</b>  | <b>257</b>  | <b>94</b>   |
| Financial (gain) losses         | 31          | 11          | -20         |
| Income taxes                    | 5           | 4           | -1          |
| Changes in other assets & liab. | 5           | -160        | -165        |
| Changes in working capital      | -292        | -471        | -179        |
| <b>Operating cash flow</b>      | <b>368</b>  | <b>187</b>  | <b>-181</b> |
| <b>Investing cash flow</b>      | <b>-376</b> | <b>-996</b> | <b>-620</b> |
| thereof capex                   | -424        | -407        | 17          |

- Income tax including reimbursements
- Changes in other assets and liabilities reflect among others:
  - Exceptional cash out due to German EEG (renewable energy law) payments
  - Variable compensation
  - Non-cash effect of IFRS15 and FX hedging with positive effects in 2021
- Working capital increase primarily driven by price effects, expected to ease in 2023
- Capex reduced below previous year level

# FY 2022: Specialty Additives and Consumer Protection continue to deliver




<sup>1</sup> Total group sales including all other segments


<sup>2</sup> Lower result due to hedging, inflated costs due to higher USD and remnant costs

# FY 2022: Positive operational development in all regions

FY 2022 sales by region [%]



Regional development of sales [€ m]



# Exceptional items (on EBIT) below previous year level mainly due to lower M&A costs

| [€ m]  | Q4/2021 |             | Q4/2022 |             | FY 2021 |             | FY 2022 |             | Comments   |
|--|---------|-------------|---------|-------------|---------|-------------|---------|-------------|--|
|  | Excep.  | Thereof D&A | Excep.  | Thereof D&A | Excep.  | Thereof D&A | Excep.  | Thereof D&A |  |
| Strategic Realignment & Restructuring            | 21      | 0           | 17      | 1           | 38      | 1           | 31      | 1           | incl. Emerald Kalama Chemical (EKC), IFF MC Integration  |
| M&A, Digitalization (incl. Chemondis) and Others | 15      | 0           | 6       | 1           | 81      | 2           | 46      | 4           | 21: incl. Theseo, INTACE acquisitions, organic leather and membrane divestments<br>22: incl. IFF MC acquisition, HPM carve out |
| Strategic IT projects                            | 13      | 0           | 1       | 0           | 31      | 0           | 32      | 0           | incl. SAP Hana Project   |
| <b>Total</b>                                     | 49      | 0           | 24      | 2           | 150     | 3           | 109     | 5           |  |

**(Gain) from settled interest rate hedge**, reflected in financial result


**-83**

# LANXESS maturity profile actively managed and well balanced


## Long-term financing secured

- Diversified financing sources
- Average interest rate of financial liabilities ~1.5%
- Planned debt reduction after receipt of JV proceeds
- All group financing executed without financial covenants
- Maturities in 2023:
  - Bank loans
  - Hybrid 1<sup>st</sup> call in June

## Liquidity and maturity profile as per December 2022



# Upcoming events H1 2023 – Proactive capital market communication



# Contact details Investor Relations



**Oliver Stratmann**  
Head of Treasury & Investor  
Relations

Tel.: +49 221 8885 9611  
Fax.: +49 221 8885 4944  
Mob.: +49 175 304 9611  
E-Mail: [oliver.stratmann@lanxess.com](mailto:oliver.stratmann@lanxess.com)

**Eva Frerker**  
Head of Investor Relations

Tel.: +49 221 8885 5249  
Fax.: +49 221 8885 4944  
Mob.: +49 151 7461 2969  
E-Mail: [eva.frerker@lanxess.com](mailto:eva.frerker@lanxess.com)

**Anja K. Siehler**  
Institutional Investors / Analysts

Tel.: +49 221 8885 1035  
Fax.: +49 221 8885 4944  
Mob.: +49 151 7461 2789  
E-Mail: [anja.siehler@lanxess.com](mailto:anja.siehler@lanxess.com)

**Markus Sieben**  
Institutional Investors / Analysts

Tel.: +49 221 8885 7344  
Fax.: +49 221 8885 4944  
Mob.: +49 151 7461 2913  
E-Mail: [markus.sieben@lanxess.com](mailto:markus.sieben@lanxess.com)

**Mirjam Reetz**  
ESG & Retail Investors

Tel.: +49 221 8885 1272  
Fax.: +49 221 8885 4944  
Mob.: +49 151 7461 3158  
E-Mail: [mirjam.reetz@lanxess.com](mailto:mirjam.reetz@lanxess.com)

Visit the  
IR website






# Abbreviations



## Consumer Protection

|                |                                  |
|----------------|----------------------------------|
| <b>MPP</b>     | Material Protection Products     |
| <b>F&amp;F</b> | Flavors & Fragrances             |
| <b>SGO</b>     | Saltigo                          |
| <b>LPT</b>     | Liquid Purification Technologies |



## Specialty Additives

|            |                              |
|------------|------------------------------|
| <b>PLA</b> | Polymer Additives            |
| <b>LAB</b> | Lubricant Additives Business |
| <b>RCH</b> | Rhein Chemie                 |



## Advanced Intermediates

|            |                                   |
|------------|-----------------------------------|
| <b>AI</b>  | Advanced Industrial Intermediates |
| <b>IPG</b> | Inorganic Pigments                |

**LANXESS**  
Energizing Chemistry